For research use only
| Cat No. | ABC-TC0089 |
| Product Type | Human Pancreas Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Disease | Pancreatic Adenocarinoma |
| Product Code | BxPc-3; BXPC-3; Bx-PC3; BXPC3; BxPC3; BxPc3; Biopsy xenograft of Pancreatic Carcinoma line-3 |
The cell line was derived from a 61 year old female with a primary adenocarcinoma of the pancreas.
BxPC-3 is a human pancreatic ductal adenocarcinoma cell line established in 1986 from the primary tumor of a 61-year-old female patient. These cells feature an epithelial, moderately differentiated morphology and grow adherently in monolayer culture. Karyotypic analysis confirms human origin, and an aneuploid status, typical of adenocarcinomas. Unlike many pancreatic lines, BxPC-3 carries a wild-type KRAS allele, but harbors a TP53 missense mutation and often shows homozygous deletions in CDKN2A/p16 and SMAD4/DPC4. The cell line secretes mucin, carcinoembryonic antigen (CEA), and pancreas-specific antigens. BxPC-3 reliably forms tumors in athymic nude mice, producing xenografts that resemble the patient’s tumor histologically and biochemically. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | BxPc-3; BXPC-3; Bx-PC3; BXPC3; BxPC3; BxPc3; Biopsy xenograft of Pancreatic Carcinoma line-3 |
| Species | Human |
| Cat.No | ABC-TC0089 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Disease | Pancreatic Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Pancreas Cancer Cell Lines |
BxPC-3 offers a versatile model for both in vitro and in vivo pancreatic cancer studies and is widely used in BxPC 3 experiments investigating tumor biology and therapeutic responses. Under optimized BxPC 3 culture conditions, it is widely used to evaluate anticancer agents, study apoptosis and cell cycle effects, and investigate tumor-stroma interactions via its mucin secretion and epithelial characteristics. It is also suitable for investigating epithelial-mesenchymal transition (EMT), angiogenesis, and metastasis mechanisms, particularly due to its expression of angiogenic factors (IL-8, VEGF) and responsiveness to EMT regulators including SNAIL. In vivo, BxPC-3 xenografts facilitate preclinical assessment of chemotherapies, targeted therapies, and tumor microenvironment modulators.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
